Abstract: The present disclosure includes systems and techniques relating to changing video playback rate. In general, one aspect of the subject matter described in this specification can be embodied in a method that includes providing a user interface for a digital video editing system, the user interface including a graphical representation of playback rate and playback duration for a sequence of digital video, and the user interface including defined points that reference respective frames in the sequence of digital video; receiving input specifying a change in playback rate for the sequence of digital video; and showing the change in playback rate and a corresponding change in playback duration for the sequence of digital video, the showing including moving one of the defined points in accordance with a new temporal position of a corresponding frame referenced by the one of the defined points.

Abstract: Recording information used in determining a licensing fee related payment is disclosed. An application is provided without a component associated with the application, where the component is associated with a licensing fee. Information associated with obtaining the component for use with the application is received. At least some of the received information is recorded, where the recorded information is used in determining licensing fee related payment to be paid for the component.

Abstract: Techniques and systems for recording video and audio in timeline sequences. In some embodiments, a method involves playing video from a timeline sequence that can include footage from portions of video tracks including at least one pre-recorded edit. In response to a selection of footage from the timeline sequence, the method can involve overwriting at least one pre-recorded edit in the timeline sequence. Each video track can correspond to a respective camera in a multiple-camera source. The footage can include one or more video clips, still images, frames, and moving images. The overwriting can occur while playing the video at a play rate faster than realtime, a play rate slower than realtime, a user-selected playing rate, during video scrubbing, or during realtime playback. The recording may involve a jump back input, and punch in and punch out locations associated with the timeline sequence.

Abstract: Frequency compensated communications reception includes compensating for frequency offset in a received signal by constructing a reference signal for comparison with a training sequence in a received signal. The reference signal is formed from basis functions and the training sequence. It is obtained by minimising a cost function J constructed from an adaptively weighted combination of basis functions, the training sequence, the received signal and a constraint requiring non-zero signal power. Multi-element antenna signals are weighted with a beamforming weight vector w in J given by formula (I), where X is a matrix of received signal samples, C is a diagonal matrix containing elements of the training sequence, F is a matrix having columns defining basis functions, v is a vector of adaptive weights, index H indicates complex conjugate transpose and ? is a Lagrange multiplier constraining beamformer power.

Abstract: The present disclosure includes systems and techniques relating to changing video playback rate. In general, one aspect of the subject matter described in this specification can be embodied in a method that includes providing a user interface for a digital video editing system, the user interface including a graphical representation of playback rate and playback duration for a sequence of digital video, and the user interface including defined points that reference respective frames in the sequence of digital video; receiving input specifying a change in playback rate for the sequence of digital video; and showing the change in playback rate and a corresponding change in playback duration for the sequence of digital video, the showing including moving one of the defined points in accordance with a new temporal position of a corresponding frame referenced by the one of the defined points.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: A lifting apparatus having a frame, a base unit and a winch unit. The frame includes wheels. The base unit is used to position an object on and is attached to the frame such that the base unit is moveable along the frame. The winch unit is attached to the frame and the base unit and provides a lifting force to the base unit in response to a control input.

Abstract: Using gene expression profiling, the present Invention identifies Protein tyrosine phosphatase IVA member 1 (PRL-1) as a diagnostic marker and therapeutic target for pancreatic cancer. The Invention therefore provides methods for prediction and detection of PRL-1 associated cancers, and evaluation of inhibitors of PRL-1. The Invention also provides a method of treating or preventing pancreatic cancer in a subject.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.